Jason Westin, MD, MS, FACP - The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care
Go online to PeerView.com/HEH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date with the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into a widening circle of non-Hodgkin lymphoma (NHL) treatment settings? Find out by watching this new activity, based on a recent live symposium at the 64th ASH Annual Meeting in New Orleans, which features a panel of experts providing guidance on the further integration of CAR-T therapy into lymphoma management. Using a ‘Seminars and Tumor Board’ format, the panelists draw on real-world cases and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including management of unique toxicities to coordination with specialized care. Upon completion of this activity, participants should be better able to: Cite the rationale, therapeutic roles, and updated evidence supporting the use of CAR-T therapy in subsets of patients with B cell non-Hodgkin lymphoma (NHL), including those with DLBCL, FL, MCL, and CLL/SLL; Apply best practices for integrating CAR-T therapy into the management of patients with NHL including processes for appropriate and equitable patient selection, referral to and care coordination with specialized centers, and delivery of appropriate pre/post-treatment and follow-up care; Incorporate novel and emerging therapies into treatment plans across a range of disease settings based on current clinical evidence and patient and disease features; and Employ appropriate, proactive, and team-based strategies to monitor for and manage toxicities associated with CD19-directed CAR-T therapy in patients with NHL, such as cytokine release syndrome and neurotoxicity, among others